Malaria prevention by use of preventive therapies with a combination of anti-malarial drugs were recommended by WHO to be administered to the most ‘at-risk’ groups who are children under 5 years and Pregnant women. These programs are commonly referred to as “Seasonal Malaria Chemoprevention” (SMC) and “Intermittent Preventive Treatment of malaria in pregnancy” (IPTp). The currently recommended combination of anti-malarial drugs for SMC remains efficacious. However, there is still an estimated gap of 12 to 18 million children who could benefit from the SMC program mainly due to the limited capacity of WHO Pre-Qualified manufacturers of the product. Our Landcent anti-malaria pill that is currently in the development pipeline with an expected market entry in 2020 will help alleviate this gap between the demand and supply, ultimately contributing towards the vision of a Malaria-free world by 2040.
You can adjust all of your cookie settings by navigating the tabs on the left hand side.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.